Clareo Health | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
Eastern Cooperative Oncology Group (ECOG) Score of 0-1.
Diagnosis of radiological progression while on or after first platinum-based systemic therapy administered for advanced or metastatic disease.
Subjects must have received one line of PD-1/PD-L1 inhibitor therapy for advanced or metastatic NSCLC. PD-1/PD-L1 inhibitor may have been given alone or in combination with other therapy.
Subjects who received PD-1/PD-L1 inhibitor for advanced disease, must have had a best response on PD-1/PD-L1 inhibitor of stable disease (SD), partial response (PR) or complete response (CR).
Subjects must have experienced disease progression more than 84 days following Cycle 1 Day 1 (C1D1) of their most recent PD-1/PD-L1 inhibitor therapy.
You may not be if
Mixed small cell and NSCLC histology.
Subject must not have leptomeningeal disease or spinal cord compression.
Subject must not have untreated, symptomatic brain metastases, or residual neurological dysfunction.
Subjects must not have received more than one line of PD-1/PD-L1 inhibitor for advanced disease.
Subjects with a known sensitizing mutation for which the Food and Drug Administration (FDA)-approved targeted therapy for NSCLC exists (e.g., EGFR, ALK, ROS1) are excluded unless previously received at least one of the approved therapy(ies).
Subjects with more than 2 lines of therapy in the advanced setting.
Pregnant or breastfeeding.
Implantable electronic medical devices (e.g. pacemaker, defibrillator) in the upper torso.
